iSpecimen Inc. (ISPC)
USD 1.15
(-6.86%)
USD 1.15
(-6.86%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 6.07 Million USD | 41.07% |
| 2022 | 4.3 Million USD | -27.32% |
| 2021 | 5.92 Million USD | -82.3% |
| 2020 | 33.48 Million USD | 24.34% |
| 2019 | 26.93 Million USD | 19.87% |
| 2018 | 22.46 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 5.7 Million USD | -6.21% |
| 2024 Q2 | 5.81 Million USD | 1.96% |
| 2023 FY | 6.07 Million USD | 41.07% |
| 2023 Q4 | 6.07 Million USD | 69.33% |
| 2023 Q3 | 3.58 Million USD | 25.51% |
| 2023 Q2 | 2.85 Million USD | -25.81% |
| 2023 Q1 | 3.85 Million USD | -10.54% |
| 2022 Q2 | 5.09 Million USD | -9.26% |
| 2022 Q4 | 4.3 Million USD | -21.9% |
| 2022 Q1 | 5.62 Million USD | -5.2% |
| 2022 FY | 4.3 Million USD | -27.32% |
| 2022 Q3 | 5.51 Million USD | 8.18% |
| 2021 Q2 | 8.92 Million USD | -75.9% |
| 2021 FY | 5.92 Million USD | -82.3% |
| 2021 Q1 | 37.04 Million USD | 10.62% |
| 2021 Q4 | 5.92 Million USD | 7.17% |
| 2021 Q3 | 5.53 Million USD | -38.03% |
| 2020 FY | 33.48 Million USD | 24.34% |
| 2020 Q3 | 31.74 Million USD | 0.0% |
| 2020 Q1 | - USD | -100.0% |
| 2020 Q4 | 33.48 Million USD | 5.49% |
| 2019 FY | 26.93 Million USD | 19.87% |
| 2019 Q4 | 26.93 Million USD | 0.0% |
| 2018 FY | 22.46 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 40.22 Million USD | 84.89% |
| Applied DNA Sciences, Inc. | 8.77 Million USD | 30.767% |
| Aspira Women's Health Inc. | 8.62 Million USD | 29.546% |
| Biodesix, Inc. | 94.51 Million USD | 93.569% |
| BioNexus Gene Lab Corp. | 1.74 Million USD | -248.925% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -80.556% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -80.556% |
| Bionano Genomics, Inc. | 118.24 Million USD | 94.86% |
| CareDx, Inc | 223.28 Million USD | 97.278% |
| Check-Cap Ltd. | 1.33 Million USD | -356.997% |
| Castle Biosciences, Inc. | 86.54 Million USD | 92.977% |
| DarioHealth Corp. | 38.24 Million USD | 84.108% |
| Exact Sciences Corporation | 3.32 Billion USD | 99.817% |
| Fulgent Genetics, Inc. | 139.82 Million USD | 95.653% |
| Guardant Health, Inc. | 1.62 Billion USD | 99.627% |
| ICON Public Limited Company | 7.74 Billion USD | 99.922% |
| IDEXX Laboratories, Inc. | 1.77 Billion USD | 99.658% |
| Illumina, Inc. | 4.36 Billion USD | 99.861% |
| Intelligent Bio Solutions Inc. | 5.59 Million USD | -8.621% |
| Standard BioTools Inc. | 159.86 Million USD | 96.198% |
| MDxHealth SA | 121.92 Million USD | 95.015% |
| 23andMe Holding Co. | 206.64 Million USD | 97.059% |
| Medpace Holdings, Inc. | 1.09 Billion USD | 99.446% |
| Myriad Genetics, Inc. | 312.9 Million USD | 98.058% |
| Mainz Biomed B.V. | 12.15 Million USD | 50.015% |
| ENDRA Life Sciences Inc. | 1.09 Million USD | -454.994% |
| NeoGenomics, Inc. | 739.69 Million USD | 99.178% |
| Neogen Corporation | 1.44 Billion USD | 99.578% |
| Inotiv, Inc. | 588.04 Million USD | 98.966% |
| Natera, Inc. | 691.79 Million USD | 99.121% |
| OpGen, Inc. | 13.44 Million USD | 54.789% |
| OPKO Health, Inc. | 622.47 Million USD | 99.024% |
| Psychemedics Corporation | 6.59 Million USD | 7.88% |
| Prenetics Global Limited | 44.01 Million USD | 86.19% |
| Prenetics Global Limited | 44.01 Million USD | 86.19% |
| Precipio, Inc. | 3.67 Million USD | -65.525% |
| Personalis, Inc. | 95.65 Million USD | 93.646% |
| RadNet, Inc. | 2.07 Billion USD | 99.707% |
| Sera Prognostics, Inc. | 25.28 Million USD | 75.96% |
| Sotera Health Company | 2.68 Billion USD | 99.774% |
| Neuronetics, Inc. | 81.64 Million USD | 92.555% |
| Star Equity Holdings, Inc. | 21.67 Million USD | 71.958% |
| Star Equity Holdings, Inc. | 21.67 Million USD | 71.958% |
| Trinity Biotech plc | 83.38 Million USD | 92.711% |
| T2 Biosystems, Inc. | 62.83 Million USD | 90.327% |
| Twist Bioscience Corporation | 152.97 Million USD | 96.027% |
| Exagen Inc. | 34.25 Million USD | 82.254% |